Aug 28, 2026
FDA approves Mimrylo, first-of-its-kind drug for polycythemia vera
The U.S. Food and Drug Administration approved Mimrylo (rusfertide), developed by Takeda Pharmaceutical and Protagonist Therapeutics, as the first drug of its kind to treat polycythemia vera, a rare blood disorder that causes overproduction of red blood cells.
3 sources
00